Polatuzumab vedotin

Drug Profile

Polatuzumab vedotin

Alternative Names: ACD79B-VCMMAE; DCDS-4501A; FCU-2711; RG-7596; RO-5541077; RO-5541077-000

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma
  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 03 Dec 2016 Updated safety and efficacy data from a phase I/II trial in B-cell lymphoma presented at the at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Efficacy and adverse events data from a phase I/II trial in Diffuse large B‐cell lymphoma (DLBCL) and Follicular lymphoma (Combination therapy, Second-line therapy or greater) presented at 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Interim efficacy and adverse events data from a phase I/II trial in Follicular lymphoma or Diffuse large B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top